Dose- and time-dependent α-synuclein aggregation induced by ferric iron in SK-N-SH cells
- First Online:
Intracellular formation of Lewy body (LB) is one of the hallmarks of Parkinson’s disease. The main component of LB is aggregated α-synuclein, present in the substantia nigra where iron accumulation also occurs. The present study was aimed to study the relationship between iron and α-synuclein aggregation.
SK-N-SH cells were treated with different concentrations of ferric iron for 24 h or 48 h. MTT assay was conducted to determine the cell viability. Thioflavine S staining was used to detect α-synuclein aggregation.
With the increase of iron concentration, the cell viability decreased significantly. At the concentrations of 5 mmol/L and 10 mmol/L, iron induced α-synuclein aggregation more severely than at the concentration of 1 mmol/L. Besides, 48-h treatment-induced aggregation was more severe than that induced by 24-h treatment, at the corresponding iron concentrations.
Ferric iron can induce α-synuclein aggregation, which is toxic to the cells, in a dose- and time-dependent way.
KeywordsParkinson’s disease α-synuclein ferric ammonium citrate
铁离子对 α- 突触核蛋白聚集的诱发作用具有剂量和时间依赖性
帕金森氏病的一个重要标志是胞浆内路易小体的形成。 路易小体的主要成分是α- 突触核蛋白的聚集体, 它和铁的积聚一同存在于黒质区。 本实验旨在研究铁和α- 突触核蛋白聚集的关系。
SK-N-SH 细胞在不同浓度的三价铁作用下, 分别孵育24 h 或48 h, 用MTT 法和硫磺素S 染色法分别检测细胞存活率、 观察α- 突触核蛋白的聚集情况。
随着铁离子浓度的升高, 细胞存活率显著下降。 其中5 mmol/L 和10 mmol/L 三价铁引起的α- 突触核蛋白的聚集相较于1 mmol/L 的三价铁引起的聚集更为严重。 此外, 在同一浓度的三价铁作用下, 孵育48 h引起的聚集比孵育24 h引起的聚集更严重。
铁离子诱发的α-突触核蛋白的聚集具有剂量和时间的依赖性, 并且α- 突触核蛋白的聚集介导了铁的毒性作用。
关键词帕金森氏病 α- 突触核蛋白 枸橼酸铁胺
Unable to display preview. Download preview PDF.
- Jiang H, Qian ZM, Xie JX. Increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice. Acta Physiol Sin 2003, 55: 571–576.Google Scholar
- Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000, 275: 18344–18349.CrossRefPubMedGoogle Scholar